MNKD logo

MannKind (MNKD) Company Overview

Profile

Full Name:

MannKind Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 28, 2004

Indexes:

Not included

Description:

MannKind Corporation (MNKD) is a biopharmaceutical company focused on developing and commercializing innovative therapies for diabetes and other serious diseases. Their main product, Afrezza, is an inhalable insulin used to manage blood sugar levels in diabetes patients, offering a convenient alternative to traditional insulin injections.

Key Details

Price

$5.63

Annual Revenue

$198.96 M(+99.42% YoY)

Annual EPS

-$0.04(+88.24% YoY)

Beta

0.92

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 3, 2017

Analyst ratings

Recent major analysts updates

Dec 20, 24 Wells Fargo
Overweight
Dec 19, 24 RBC Capital
Outperform
Aug 28, 24 Oppenheimer
Outperform
Jun 13, 24 Rodman & Renshaw
Buy
May 9, 24 Cantor Fitzgerald
Overweight
Mar 15, 24 Cantor Fitzgerald
Overweight
Feb 28, 24 Cantor Fitzgerald
Overweight
Jan 4, 24 HC Wainwright & Co.
Buy
Oct 10, 23 Wedbush
Outperform
Aug 14, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

MannKind Expands Executive Leadership Team
MannKind Expands Executive Leadership Team
MannKind Expands Executive Leadership Team
MNKD
globenewswire.comJanuary 6, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MNKD
globenewswire.comDecember 16, 2024

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MNKD
globenewswire.comDecember 11, 2024

India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.

MannKind (MNKD) Matches Q3 Earnings Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
MNKD
zacks.comNovember 7, 2024

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.

MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference
MNKD
globenewswire.comNovember 5, 2024

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MNKD
globenewswire.comNovember 4, 2024

Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
MNKD
zacks.comNovember 1, 2024

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MNKD
globenewswire.comOctober 31, 2024

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Why MannKind (MNKD) Could Beat Earnings Estimates Again
Why MannKind (MNKD) Could Beat Earnings Estimates Again
Why MannKind (MNKD) Could Beat Earnings Estimates Again
MNKD
zacks.comOctober 7, 2024

MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
MNKD
seekingalpha.comOctober 3, 2024

MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases.

FAQ

  • What is the ticker symbol for MannKind?
  • Does MannKind pay dividends?
  • What sector is MannKind in?
  • What industry is MannKind in?
  • What country is MannKind based in?
  • When did MannKind go public?
  • Is MannKind in the S&P 500?
  • Is MannKind in the NASDAQ 100?
  • Is MannKind in the Dow Jones?
  • When was MannKind's last earnings report?
  • When does MannKind report earnings?
  • Should I buy MannKind stock now?

What is the ticker symbol for MannKind?

The ticker symbol for MannKind is NASDAQ:MNKD

Does MannKind pay dividends?

No, MannKind does not pay dividends

What sector is MannKind in?

MannKind is in the Healthcare sector

What industry is MannKind in?

MannKind is in the Biotechnology industry

What country is MannKind based in?

MannKind is headquartered in United States

When did MannKind go public?

MannKind's initial public offering (IPO) was on July 28, 2004

Is MannKind in the S&P 500?

No, MannKind is not included in the S&P 500 index

Is MannKind in the NASDAQ 100?

No, MannKind is not included in the NASDAQ 100 index

Is MannKind in the Dow Jones?

No, MannKind is not included in the Dow Jones index

When was MannKind's last earnings report?

MannKind's most recent earnings report was on Nov 7, 2024

When does MannKind report earnings?

The next expected earnings date for MannKind is Feb 27, 2025

Should I buy MannKind stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions